Breaking News

Xencor Receives Janssen R&D Milestone

January 17, 2013

Will use Xtend technology for therapeutic antibody

Xencor, Inc. has received a milestone payment from Janssen R&D for the use of Xencor's Xtend half-life extension technology in a therapeutic antibody. The companies had entered a technology license agreement in 2009. The antibody target and payment amount were not disclosed.
 
"There has been significant interest in Xtend technology because of the impact it has on the pharmacokinetic properties of antibodies, and we are seeing Xencor technology license agreements with partners translate into promising pipeline programs," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.

Related Contract Manufacturing:

  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus